2026-04-30T02:04:05Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/ojpg.000013 2024-04-30 PTZ.OJPG:VOL9

A sirtuin 6 activator in the pipeline: New perspectives in depressive disorder treatment Ana Carolina de Oliveira Pereira Gabriel Almeida Mendonça da Silva José C. BarrosRaoni Schroeder Borges Gonçalves<p>Major Depressive Disorder (MDD) is among the most prevalent mental illnesses worldwide. Its symptoms include persistent feelings of sadness, loss of interest in previously enjoyed activities, and a lack of motivation for daily tasks. While FDA-approved medications are available, they often come with side effects, especially those targeting monoamine neurotransmitters like SSRIs and SNRIs. Thus, there is a need for innovative medications with different mechanisms of action. Sp-624, a derivative of griseofulvin, is currently undergoing clinical trials for MDD treatment. It acts as a sirtuin 6 (SIRT6) activator, offering a novel approach to treating this disorder. This article discusses the biochemical aspects related to the mechanism of action of sp-624, provides a brief overview of related patents, and highlights ongoing clinical trials involving this substance.&nbsp;</p> Open Journal of Proteomics and Genomics - Peertechz Publications 2024-04-30 Commentary https://doi.org/10.17352/ojpg.000013 en Copyright © Ana Carolina de Oliveira Pereira et al.